Eli Lilly shares fell 2% in premarket trading on Friday. The decline followed the release of weekly prescription data for the period ending April 17.
Total prescriptions for Zepbound decreased by approximately 2% from the prior week. Novo Nordisk’s competing drug, Wegovy, recorded 7% weekly growth during the same timeframe. Mounjaro prescriptions saw a slight increase.
Lilly’s newly launched oral weight-loss drug, Foundayo, recorded approximately 3,700 prescriptions in its second week. Analysts are monitoring these trends to assess Lilly’s competitive standing in the expanding obesity market.